An observational study in Intracranial Stenosis, sponsored by Acandis GmbH. Recruiting at 16 sites in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-01.
Sponsored by Acandis GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Constriction, Pathologic with a site in Germany — 6 open to participants now, 8 under way, none of them phase 3. Constriction, Pathologic · Germany.
Among the 43 studies in Constriction, Pathologic with a site in Germany, this one is the 7th largest by planned enrollment of the 20 observational ones that give a count, is one of 4 that started in 2016, is one of 20 observational ones, and was the 28th registered.
457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.
Browse Constriction, Pathologic studies →6 of the 43 studies in Constriction, Pathologic with a site in Germany are open now. Recruiting first, the newest first:
Phenox GmbH · Sites in Germany, France, Italy and 2 more countries
Insel Gruppe AG, University Hospital Bern · Sites in Germany, Switzerland
Ages 18+
JOTEC GmbH · Sites in Germany
Ages 18+
ZygoFix · Sites in Germany, Italy
Ages 18–75
University Hospital Tuebingen · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2016.
This study's planned enrollment of 150 is above the median of 84 across 144 observational studies indexed under Constriction, Pathologic.
Median enrollment 70 across the 23 interventional studies, 122 across the 20 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Acandis GmbH is the lead sponsor of 11 studies on the registry; 7 are open to participants now.
Acandis GmbH has 1 study filed under Constriction, Pathologic — fewer than ten, so there is no comparison to draw.
1 of the studies in Constriction, Pathologic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05149755Medtronic CardiovascularEvolut™ EXPAND TAVR II Pivotal Trial | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Constriction, Pathologic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ASSISTENT is designed to collect comprehensive information on technical and clinical safety of the use of Credo® stent together with the NeuroSpeed® PTA balloon catheter in clinical practice in an open registry.
ASSISTENT is subdivided into two components. The first part only requires recording of data acquired in routine clinical practice during the treatment of patients with intracranial stenosis with the self-expandable Credo® stent until discharge. This comprises demographic data, data concerning the qualifying clinical event, limited data on medical history and medication, information about the intervention including technical success and periprocedural complications or events, and information about events and clinical status during the in-hospital treatment until hospital discharge.
The second part of the registry consists of a follow-up visit 30 days after the interventional procedure which will be conducted outside of clinical practice.
All patients over 18 with symptomatic intracranial artery stenosis treated with the self-expandable Credo® stent in the participating sites in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients treated with Credo® Stent and NeuroSpeed® PTA balloon catheter in the clinical routine
Device: Credo® Stent, NeuroSpeed® PTA balloon catheter
a self-expanding stent is used together with a PTA balloon catheter
Rate of Technical Success
• Technical Success
Time frame: During interventional procedure
Number of Patients with Periprocedural Vascular Events
* Intracranial haemorrhage (symptomatic / asymptomatic) * Death * TIA in the region of the target vessel * Non-disabling ischemic stroke (MRS 0-2) in the region of the target vessel * Disabling ischemic stroke (MRS 3-6) in the region of the target vessel * TIA outside the region of the target vessel * Non-disabling ischemic stroke (MRS 0-2) outside the region of the target vessel * Disabling ischemic stroke (MRS 3-6) outside the region of the target vessel
Time frame: Periprocedural, until 30 days after the interventional procedure
Number of Patients with Cerebrovascular events
* Intracranial haemorrhage (symptomatic / asymptomatic) * Death * TIA in the region of the target vessel * Non-disabling ischemic stroke (MRS 0-2) in the region of the target vessel * Disabling ischemic stroke (MRS 3-6) in the region of the target vessel * TIA outside the region of the target vessel * Non-disabling ischemic stroke (MRS 0-2) outside the region of the target vessel * Disabling ischemic stroke (MRS 3-6) outside the region of the target vessel
Time frame: At hospital discharge - befor the patient leaves the hospital after the intervention; up to 2 weeks, whichever came first
Number of Patients with Cerebrovascular Events
* Intracranial haemorrhage (symptomatic / asymptomatic) * Death * TIA * Non-disabling ischemic stroke (MRS 0-2) * Disabling ischemic stroke (MRS 3-6) * Interventional re-treatment of the target vessel
Time frame: 30 days after the interventional procedure
Number of Patients with Dissection of the target vessel
Time frame: During interventional procedure
Number of Patients with Occlusion of the target vessel
Time frame: 30 days after the interventional procedure
Number of Patients with Myocardial infarction
Time frame: 30 days after the interventional procedure
Number of Patients with Severe extracranial hemorrhage (requiring surgical treatment or transfusion)
Time frame: 30 days after the interventional procedure
Plan to share: No
No publications or documents are linked to this record.
Started May 2016 (actual). Primary completion is estimated for Mar 2025, 106 months after the start.
Of 64 observational studies under Constriction, Pathologic, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 106 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acandis GmbH